Annual 2016 Results Presentation NIREUS AQUACULTURE S.A. Table of - - PowerPoint PPT Presentation

▶
annual 2016 results presentation nireus aquaculture s a
SMART_READER_LITE
LIVE PREVIEW

Annual 2016 Results Presentation NIREUS AQUACULTURE S.A. Table of - - PowerPoint PPT Presentation

Dec 11, 2023 238 likes •497 views

Athens Greece | 31 March 2017 Annual 2016 Results Presentation NIREUS AQUACULTURE S.A. Table of Contents Pages I. Our

slide-1
SLIDE 1

Annual 2016 Results Presentation NIREUS AQUACULTURE S.A.

Athens Greece | 31 March 2017

slide-2
SLIDE 2

2

Table of Contents

Key points Pages I. Our Vision……………………………………………………………………………………..……………………………………….…3 II. Profile…………………………………………………………………………………………………………………………………..4-13 III. Main Events…………………………………………………………………………………………………………………………....14 IV. Sales by Business Sector…………………………………………………………………………………………………..……..15 V. Sales evolution………………………………………………………………………….....…………………………………………16 VI. FY 2016 Performance…………………………………………………………...…………………………………….……..17-22 VII. Appendix A – Seabass & Seabream Industry ………………………………………....………..………...………….23

  • VIII. Appendix B – IFRS 13 & IAS 41 for biological assets………………………………………....………..…………..24

Disclaimer This presentation has been prepared solely for informational purposes. Any projections or other estimates in this presentation, including estimates of returns or performance, comments with respect to our

  • bjectives and strategies, or the results of our operations and business, are forward-looking statements based upon certain assumptions that may be wrong. These assumptions may be influenced by factors within
  • r beyond our control, and actual results may differ materially from any estimates and projections. Factors influencing actual results include but are not limited to fluctuations in fish prices and raw material prices,

the effects of competition in the areas in which we operate, changes in the economic environment, regulatory and economic conditions. This presentation is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any trading strategy. No part of this presentation may be construed as constituting investment advice or a recommendation to enter into any transaction. No representation or warranty is given with respect to the accuracy or completeness of the information contained in this presentation, and no claim is made that any future offer to transact any securities will conform to any terms that may be contained herein. Before entering into any transaction, investors should determine any economic risks and benefits, as well as any legal, tax and accounting consequences of doing so, as well as their ability to assume such risks, without reliance on the information contained in this presentation

slide-3
SLIDE 3

3 Key points

Our Vision

“To include high nutritional Mediterranean fish in consumers’ diet around the globe”

slide-4
SLIDE 4

4 Key points

Profile

  • Leading food retailers, distributors, processors and fish farmers are capturing the growing market demand for

healthy and sustainable seafood with NIREUS products.

  • Leading food retailers, distributors, processors and fish farmers are capturing the growing market demand for

healthy and sustainable seafood with NIREUS products.

35 + 350 1,5 million fish

Countries Customers delivered every week

Serving our customers is a top priority

  • We enable our customers to grow their business by offering the largest selection of high quality products and

integrated solutions adapted to their needs.

  • We enable our customers to grow their business by offering the largest selection of high quality products and

integrated solutions adapted to their needs.

slide-5
SLIDE 5

5 Key points

Profile

In 2016 Nireus group delivered more than 100 million meals

Note : Assuming one meal = 140 gr of fish fillet

slide-6
SLIDE 6

6 Key points

Profile

  • Less than 0,01% quality claims
  • Less than 0,01% quality claims
slide-7
SLIDE 7

7 Key points

Profile

We create value for our customers by

  • ffering them tools to grow their business
  • The Largest Selection & Product Range of

Mediterranean Fish

  • The Largest Selection & Product Range of

Mediterranean Fish

  • Year-round Supply
  • Year-round Supply
  • Vertically Integrated Operations
  • Vertically Integrated Operations
  • Infrastructure, Product & Market Know-How
  • Infrastructure, Product & Market Know-How
  • Complete Sales Support
  • Complete Sales Support
  • Innovative & Sustainable Aquaculture Practices
  • Innovative & Sustainable Aquaculture Practices
  • High Standards in Food Safety & Environmental

Management

  • High Standards in Food Safety & Environmental

Management

Highly rated by our customers in 2016 Customer Satisfaction Survey

slide-8
SLIDE 8

8 Key points

Profile - Product portfolio

A prized portfolio for retailers, distributors, processors and aquaculture producers FISH PRODUCTS

Our fish grow in a unique environment. They are raised in a natural and wholesome manner in the clear blue waters of Greece and Spain, in sea farms well-tended by our skilled and caring staff who are present 24 hours a day, 7 days per week. Their premium quality is ensured by low stocking density levels, being 2% fish to 98% water. Their appearance, taste, texture and color derive from our own carefully selected brood stock, our fish feed made to best suit their particular life stage needs and from NIREUS’ extensive know-how in aquaculture since 1988. They are available in all product forms :

  • Fresh and frozen
  • Whole
  • Gutted
  • Fillets
  • Pre-packaged

Gilthead sea bream European sea bass Pargus Mearge

slide-9
SLIDE 9

9 Key points

Profile - Product portfolio

INDUSTRIAL PRODUCTS

slide-10
SLIDE 10

10 Key points

Profile – Production Facilities

Processing 26 Fish farming units 4 Hatchery units 6 Packing units 1 Processing unit 3 Pre-fattening units 2 Fish Feed factories (capacity 90.000 tons)

Production facilities in Greece and Spain

Greece Spain Fish Feed Plants Hatchery Units Fish farming Packing units Processing unit

  • Pre-Fattening

Units Fish Farming

slide-11
SLIDE 11

11 Key points

Profile - Vertically Integrated Operations

NIREUS, being a vertical producer, controls the entire value chain of all its products, ensuring that every stage of production adheres to the best industry practices. NIREUS, being a vertical producer, controls the entire value chain of all its products, ensuring that every stage of production adheres to the best industry practices.

slide-12
SLIDE 12

12 Key points

Profile - Pioneering Technology

The most advanced breeding selection program for Mediterranean fish Cutting-edge technology in Long-standing cooperation with Universities and leading research institutes

slide-13
SLIDE 13

13 Key points

Profile – Main Customers in Europe

slide-14
SLIDE 14

14

  • Restructuring of the loans of SEAFARM IONIAN SA
  • Restructuring of the loans of SEAFARM IONIAN SA

Main events in 2016

Key points

  • Increase in the Company’s Share Capital
  • Increase in the Company’s Share Capital
  • Removal of the trading of NIREUS AQUACULTURE SA shares from the “under surveillance”
  • Removal of the trading of NIREUS AQUACULTURE SA shares from the “under surveillance”

The refinancing of the loans of merged company SEAFARM IONIAN of an amount of € 20,9 million was concluded on 14.01.2016, subsequent to the merger by absorption of the company with its subsidiary SEAFARM IONIAN SA (22.12.2015). Following the merger of SEAFARM IONIAN and approval of the trading of new shares as at 24.03.2016, 31.582.478 shares of a value of € 9.474.743 were issued Furthermore, during the year 2016, 884.404 shares, of a value of € 265.321 from the conversion of bonds which the bondholders held from the convertible bond loan, were issued As a result, the Company’s share capital as at 31.12.2016, amounted to € 87.449.210,40 divided into 291.497.368 common shares with voting rights, at a par value of € 0,30 each. The trading of the company’s shares in the Main Market of the Athens Stock Exchange is effective as of 12 February, 2016.

slide-15
SLIDE 15

15

Sales by Business Sector

Sales evolution Sales by Business Sector FY2015 & FY2016 (€ mil.)

  • Fish farming sales increased by € 9.7 mil
  • Fish farming sales increased by € 9.7 mil
  • Fish feed sales increased by € 2.0 mil
  • Fish feed sales increased by € 2.0 mil
  • Other sales increased by € 0,7 mil
  • Other sales increased by € 0,7 mil

0,0% 20,0% 40,0% 60,0% 80,0% 100,0%

Fish Farming Fish Feed Other

90,2% 3,6% 6,2%

Sales by Business Sector FY2016 (%)

168,6 178,3

FISH FARMING

FY2015 FY2016 5,1 7,1

FISH FEED

FY2015 FY2016 11,7 12,4

OTHER

FY2015 FY2016

Fish farming = fish + juvenile sales (own production + merchandise) Fish farming = fish + juvenile sales (own production + merchandise) Other = fish farming equipment and aviculture product sales Other = fish farming equipment and aviculture product sales

slide-16
SLIDE 16

16

Sales Evolution

Sales evolution

2011 2012 2013 2014 2015 2016 75% 77% 78% 80% 81% 79% 25% 23% 22% 20% 19% 21% EXPORT SALES DOMESTIC SALES

Sales Distribution (%) FY2011-FY2016

0% 20% 40% 60% 80% Greece E.U. Other 21% 68% 11%

Sales by Region FY2016

0% 20% 40% 60% 80%

Greece E.U. Other

19% 70% 10%

Sales by Region FY2015

Greece 41,7 EU 134,9 Other 21,2 Total 197,8 Exports 156,1 FY 2016 Greece 35,8 EU 130,5 Other 19,1 Total 185,4 Exports 149,6 FY 2015

slide-17
SLIDE 17

17

  • Group sales in 2016 amounted to € 197,8 mil., as compared to € 185,4 million, during the prior year 2015

marking an increase of 6,7%.

  • Group sales in 2016 amounted to € 197,8 mil., as compared to € 185,4 million, during the prior year 2015

marking an increase of 6,7%.

Financial Performance

Key points

  • Operating EBITDA (prior to the effect of the valuation of biological assets at fair value) amounted to € 27,3

million versus € 22,3 million in 2015 presenting an increase of 22,4%. The increase in operating EBITDA was mainly attributed to increased sales volumes and to a reduction in the fish production cost.

  • Operating EBITDA (prior to the effect of the valuation of biological assets at fair value) amounted to € 27,3

million versus € 22,3 million in 2015 presenting an increase of 22,4%. The increase in operating EBITDA was mainly attributed to increased sales volumes and to a reduction in the fish production cost.

  • Total pre-tax results of 2016 amounted to profits of € 7,9 million versus profits of € 68,1 million in 2015. It is

noted that the results of 2015 include gains of € 57,2 million from the fair value measurements of loan borrowings from the share capital increase.

  • Total pre-tax results of 2016 amounted to profits of € 7,9 million versus profits of € 68,1 million in 2015. It is

noted that the results of 2015 include gains of € 57,2 million from the fair value measurements of loan borrowings from the share capital increase.

  • Total after tax profits of the year amounted to € 10,9 million as compared to profits of € 60,1 million in 2015

which, as previously mentioned, include the profits from the valuation at fair value of the loan borrowings refinancing and the share capital increase.

  • Total after tax profits of the year amounted to € 10,9 million as compared to profits of € 60,1 million in 2015

which, as previously mentioned, include the profits from the valuation at fair value of the loan borrowings refinancing and the share capital increase.

slide-18
SLIDE 18

18

  • Positive operating cash flows continued in 2016 which amounted to € 4,8 million as compared to € 5,9 million

in 2015.

  • Positive operating cash flows continued in 2016 which amounted to € 4,8 million as compared to € 5,9 million

in 2015. Key points

  • Investments in fixed assets amounted to € 6,6 million as compared to € 6,9 million in 2015.
  • Investments in fixed assets amounted to € 6,6 million as compared to € 6,9 million in 2015.
  • Loan borrowings, prior to the effect of the valuation of the Group’s loans at fair value, amounted to € 184,6

million versus € 187,3 million as at 31/12/2015.

  • Loan borrowings, prior to the effect of the valuation of the Group’s loans at fair value, amounted to € 184,6

million versus € 187,3 million as at 31/12/2015.

  • The Company’s share capital amounted to € 87.449.210,40 divided into 291.497.368 shares with a nominal

value € 0,30 each

  • The Company’s share capital amounted to € 87.449.210,40 divided into 291.497.368 shares with a nominal

value € 0,30 each

Net Debt, prior to the effect of the valuation of the Group’s loans at fair value, amounted to € 171,6 million versus € 171,5 million as at 31/12/2015. Net Debt, after the effect of the valuation of loans at fair value, amounted to € 154,7 million versus € 153,1 million in 2015.

  • The Group’s equity amounted to € 132,1 million as at 31/12/2016.
  • The Group’s equity amounted to € 132,1 million as at 31/12/2016.

Financial Performance

slide-19
SLIDE 19

19

Balance Sheet

Financials

Balance Sheet

Assets

(€ mil.)

FY2016 FY2015 Property Plant and Equipment 76,79 77,25 Goodwill 30,30 30,36 Biological non-current assets 65,87 60,83 Other non-current assets 16,16 16,05 Total non-current assets 189,12 184,49 Biological current assets 114,75 118,77 Inventories 10,46 9,49 Trade Receivables 37,17 33,16 Other current assets 9,89 9,54 Restricted Cash 4,24 6,98 Cash & equivalents 8,75 8,78 Total current assets 185,26 186,73 Assets available for sale

  • Total assets

374,37 371,21

Equity and liabilities

(€ mil.)

FY2016 FY2015 Shareholders' equity 132,12 121,19 Non-controlling interests

  • Total shareholders' equity and non-controlling

interests 132,12 121,19 L/T bank borrowings 149,50 124,91 Deferred income tax liabilities 8,64 12,08 Other non-current liabilities 11,37 12,94 Total non-current liabilities 169,51 149,93 Trade & other payables 45,87 44,59 Current bank borrowings 18,20 44,00 Other current liabilities 8,66 11,51 Total current liabilities 72,74 100,10 Liabilities of assets available for sale

  • Total liabilities

242,25 250,02 Total shareholders' equity and liabilities 374,37 371,21

  • Trade & other receivables increased by € 4.36 mil.
  • Trade & other receivables increased by € 4.36 mil.
  • Trade & other payables, increased by € 1.28 mil.
  • Trade & other payables, increased by € 1.28 mil.
  • Total liabilities decreased by € (7.77) mil.
  • Total liabilities decreased by € (7.77) mil.
  • Total liabilities, excluding interest bearing loans and

borrowings, decreased by € (6.57) mil.

  • Total liabilities, excluding interest bearing loans and

borrowings, decreased by € (6.57) mil.

  • Cash and Cash Equivalents amounted to € 8.75 mil
  • Cash and Cash Equivalents amounted to € 8.75 mil
  • Restricted cash of € 4 mil has been pledged as

collateral against long term bank borrowings

  • Restricted cash of € 4 mil has been pledged as

collateral against long term bank borrowings

slide-20
SLIDE 20

20

Income Statement

Financials

  • Group sales in 2016 amounted to € 197,8 mil., as

compared to € 185,4 million, during the prior year 2015 marking an increase of 6,7%.

  • Group sales in 2016 amounted to € 197,8 mil., as

compared to € 185,4 million, during the prior year 2015 marking an increase of 6,7%.

Income Statement

(€ mil.)

FY2016 FY2015 Biological Sales 170,42 157,57 Non-Biological Sales 27,39 27,83 Total Sales 197,81 185,40 Effect of measurement of biological assets at fair value (*) (0,11) 15,15 Raw material consumption (99,53) (95,42) Salaries & personnel expenses (28,95) (27,49) 3rd party fees and benefits (21,95) (21,26) Other operating expenses (26,49) (24,61) Other income 1,65 2,51 EBITDA after biological adjustment 22,44 34,26 Biological adjustment (4,87) 11,92 EBITDA before biological adjustment 27,31 22,34 Earnings / (loss) before interest and taxes (EBIT) 16,95 28,06 Earnings / (loss) before taxes (EBT) 7,86 68,06 Tax 3,06 (8,00) Earnings / (loss) after taxes (EAT) 10,92 60,06 Equity holders of the parent 10,92 59,25 Non-controlling interests

  • 0,81

Earnings per share (€) 0,0385 0,5678

(*) equal to (ending inventory - purchases – beginning inventory) of biological assets

  • Operating EBITDA (prior to the effect of the

valuation of biological assets at fair value) amounted to € 27,3 million versus € 22,3 million in 2015 presenting an increase of 22,4%.

  • Operating EBITDA (prior to the effect of the

valuation of biological assets at fair value) amounted to € 27,3 million versus € 22,3 million in 2015 presenting an increase of 22,4%.

slide-21
SLIDE 21

21

Cash Flow Statement

Financials

Cash Flow (€ mil.) FY2016 FY2015 Profit before tax 7,86 68,06 Depreciation 6,29 6,90 Miscellaneous other charges 6,35 (39,38) Fair value adjustment 4,87 (11,92) Reduction /(increase) of inventories (6,86) (3,66) Reduction /(increase) of receivables (4,53) (2,16) (Reduction)/increase of trade & other payables (1,47) (2,01) Interest expenses paid (7,39) (9,70) Taxes paid (0,33) (0,25) Cash flow from operating activities 4,77 5,88 (Investments) (6,59) (6,91) Divestments 0,21 2,76 Subsidies & received interest 1,57 0,08 Cash flow from investing activities (4,80) (4,08) Cash flow from financing activities 0,01 1,18 Total cash flow reporting period (0,02) 2,99 Cash and cash equivalents at the beginning of the period 8,78 5,44 Foreign exchange adjustments

  • 0,35

Cash of items for sale

  • Cash and cash equivalents at the end of

the period 8,75 8,78

  • Positive operating cash flows continued in 2016

which amounted to € 4,8 million as compared to € 5,9 million in 2015.

  • Positive operating cash flows continued in 2016

which amounted to € 4,8 million as compared to € 5,9 million in 2015.

  • Investments in fixed assets amounted to € 6,6

million as compared to € 6,9 million in 2015.

  • Investments in fixed assets amounted to € 6,6

million as compared to € 6,9 million in 2015.

slide-22
SLIDE 22

22 Key points

CEO comments

Our accomplishments were the result of all employees’ commitment towards the achievement of our goals ” “We are continuing our upward path to operating profitability which had started in 2015.

Antonis Chachlakis, CEO

slide-23
SLIDE 23

23 Key points

Appendix A : Seabass and Seabream Industry

200.000 400.000 600.000 800.000 1.000.000 1.200.000 2011 2012 2013 2014 2015 2016

Estimated juvenile production (in pcs)

Greece Turkey Italy France Spain Others

100.000 200.000 300.000 400.000 2011 2012 2013 2014 2015 2016

Harvested quantities Seabass and Seabream (in tons)

Others Cyprus Croatia Portugal France Italy Spain Turkey Greece

  • The main parameter that is taken into account

for the estimation of fish availability is the juvenile placement for fattening by farming companies

  • The main parameter that is taken into account

for the estimation of fish availability is the juvenile placement for fattening by farming companies

Source : Kontali Analysis

  • The increased juvenile production quantities,

mainly form Turkish farmers, is expected to lead to increased supply of fish quantities in 2017 that will result in a decline of selling prices

  • The increased juvenile production quantities,

mainly form Turkish farmers, is expected to lead to increased supply of fish quantities in 2017 that will result in a decline of selling prices

  • In 2016 the industry’s total harvested volume

reached 304.000 tons

  • In 2016 the industry’s total harvested volume

reached 304.000 tons

slide-24
SLIDE 24

24 Appendix A Fish farming companies are required to report the fair value of their biological assets at each reporting period in accordance with IFRS 13 & IAS 41. Mature biological assets (ready to be sold) are reported in the B.S. as current assets while immature biological assets are presented as non- current assets. The fair value of mature biological assets is calculated as volume (in kg) x market price at the end of the reporting period (exit price of the principal market less costs to sell). Key drivers include the quantity and size distribution of biological assets as well as the market price at the time of the valuation. Sales in the I.S. are distinguished between biological and non-

  • biological. Biological sales represent sales of fish and juveniles of own
  • production. Non-biological sales represent sales of fish/juveniles as

merchandise, sales of fish feed, equipment and other products. The effect from the measurement of biological assets at fair value is derived by the following formula : Fair value of biological assets at the end of the period (-) Purchases of biological assets (-) Fair value of biological assets at the beginning of the period = Effect of measurement of biological assets at fair value Fair value of biological assets (B.S.) Volume x Price Key Drivers Δ Volume Δ Price Biological Sales (I.S.) The sales of fish & juveniles of own production Non-biological sales (I.S.) The sales of fish & juveniles as merchandise, fish feed, equipment and other products Total Sales (I.S.) Sales of biological + Non-biological products Effect from the measurement of biological assets at fair value The difference between the fair value of biological assets at the beginning and the end of the period

Appendix B : IFRS 13 & IAS 41 for biological assets

slide-25
SLIDE 25

25

Communication

  • Mr. Stratis Elissaios, Group CFO
  • Tel. +30 210 66 98 224

Email : s.elissaios@nireus.com

  • Mr. Nontas Leontidis, Group Financial Controller & IR Officer
  • Tel. +30 210 66 98 225, Mob. +30 693 66 98 332

Email : n.leontidis@nireus.com, irodpt@nireus.com

Legal Notice This presentation has been prepared solely for informational purposes. Any projections or other estimates in this presentation, including estimates of returns or performance, comments with respect to our objectives and strategies, or the results of our operations and business, are forward-looking statements based upon certain assumptions that may be

  • wrong. These assumptions may be influenced by factors within or beyond our control, and actual results may differ materially from any estimates and projections. Factors influencing

actual results include but are not limited to fluctuations in fish prices and raw material prices, the effects of competition in the areas in which we operate, changes in the economic environment, regulatory and economic conditions. This presentation is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any trading strategy. No part of this presentation may be construed as constituting investment advice or a recommendation to enter into any transaction. No representation or warranty is given with respect to the accuracy or completeness of the information contained in this presentation, and no claim is made that any future offer to transact any securities will conform to any terms that may be contained herein. Before entering into any transaction, investors should determine any economic risks and benefits, as well as any legal, tax and accounting consequences of doing so, as well as their ability to assume such risks, without reliance on the information contained in this presentation.